Senju Pharmaceutical patented a method for treating retinal epithelium and nerve diseases by administering laminin 511 or its fragments along with retinal pigment epithelial cells or nerve cells. The technique aims to address conditions like retinitis pigmentosa, macular degeneration, and glaucoma. GlobalData’s report on Senju Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Senju Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Senju Pharmaceutical's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of retinal and nerve diseases with laminin and cells
A recently granted patent (Publication Number: US11918630B2) discloses a method for treating diseases, disorders, or conditions of a nerve that require cell transplantation in a subject. The method involves administering either laminin 511 or its fragments along with nerve cells or retinal pigment epithelial cells to the subject. The conditions that can be treated using this method include retinitis pigmentosa, macular degeneration, Stargardt disease, glaucoma, or optic neuropathy.
Specifically, the patent claims highlight the use of laminin 511-E8 fragment as an agent for treating nerve-related conditions in subjects. This method offers a potential treatment option for individuals suffering from various nerve-related diseases and disorders. By combining the administration of specific agents with nerve cells or retinal pigment epithelial cells, the patent aims to address the underlying causes of conditions such as retinitis pigmentosa, macular degeneration, Stargardt disease, glaucoma, or optic neuropathy. This innovative approach could potentially lead to advancements in the field of cell transplantation therapy for nerve-related ailments.
To know more about GlobalData’s detailed insights on Senju Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
